Skip to main content
SpringerLink
Log in

Clinical Trials on Cell Therapy for Perinatal Brain Injury: Challenges and Opportunities

  • Chapter
  • First Online:
Cell Therapy for Perinatal Brain Injury

  • 398 Accesses

Abstract

We performed a review of the literature and identified 9 published studies that conducted clinical trials to identify the safety, feasibility, and efficacy of cell therapy and 16 ongoing clinical trials. Most studies showed an improvement of motor function compared to the control groups, and the improvement appeared in the relatively early stage after transplantation. However, the mechanism by which stem cells help to recover neurological cells remains unclear. Many of the studies or trials were in phase 1 or phase 2; thus, it is too early to conclude the effectiveness of cell therapy. Therefore, further clinical trials at an advanced stage and experimental research using animal models are needed to elucidate the mechanism and efficacy. Conversely, the pharmaceutical agencies that review new drugs and medical devices have installed various systems and policies to accelerate the development of new drugs. For instance, the Pharmaceuticals and Medical Devices Agency (PMDA) has established a special department for cellular and tissue-based products; furthermore, the PMDA has launched a conditional time-limited marketing authorization system. This system makes it possible to rapidly provide new drugs to patients. In addition, the PMDA has installed an accelerated assessment system to facilitate the development of drugs for diseases without route-based treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. An Y. Efficacy of stem cell transplantation compared to rehabilitation treatment of patients with cerebral paralysis (CP). 2013–2015. https://clinicaltrials.gov/ct2/show/NCT01929434?term=NCT01929434&rank=1. Accessed 30 Nov 2015.

  2. Baumgartner J. Safety of autologous human umbilical cord blood treatment for perinatal arterial ischemic stroke. 2015–2019. https://clinicaltrials.gov/ct2/show/NCT02460484?term=NCT02460484&rank=1. Accessed 30 Nov 2015.

  3. Cairo SM. Autologous cord blood and human placental derived stem cells in neonates with severe hypoxic-ischemic encephalopathy (HPDSC+HIE). 2016–2019. https://clinicaltrials.gov/ct2/show/NCT02434965?term=NCT02434965&rank=1. Accessed 30 Nov 2015.

  4. Carroll EJ, Sekul E, Bollag R, Ameri A, Neunert C, Johnson T et al. Safety and effectiveness of cord blood stem cell infusion for the treatment of cerebral palsy in children. 2010–2016. https://clinicaltrials.gov/ct2/show/NCT01072370?term=NCT01072370&rank=1. Accessed 30 Nov 2015.

  5. Cotten MC, Fisher AK, Kurtzberg J, Song A, Goldstein R, Goldberg R et al. Cord blood for neonatal hypoxic-ischemic encephalopathy. 2008–2015. https://clinicaltrials.gov/ct2/show/NCT00593242?term=NCT00593242&rank=1. Accessed 30 Nov 2015.

  6. Cox SC. Safety and effectiveness of banked cord blood or bone morrow stem cells in children with cerebral palsy (CP). (ACT for CP). 2013–2017. https://clinicaltrials.gov/ct2/show/NCT01988584?term=NCT01988584&rank=1. Accessed 30 Nov 2015.

  7. Kim M. Allogeneic umbilical cord blood therapy for stroke. 2013–2015. https://clinicaltrials.gov/ct2/show/NCT01884155?term=NCT01884155&rank=1. Accessed 30 Nov 2015.

  8. Kim M, Kang M, Kim S, Jang S, Min K, Lee J, et al. Allogeneic umbilical cord blood therapy in children with CP. 2013–2015. https://clinicaltrials.gov/ct2/show/NCT02025972?term=NCT02025972&rank=1. Accessed 30 Nov 2015.

  9. Kim M, Kang M, Kim S, Jang S, Min K, Yoo S. Umbilical cord blood therapy for global developmental delay. 2012–2014. https://clinicaltrials.gov/ct2/show/NCT01769716?term=NCT01769716&rank=1. Accessed 30 Nov 2015.

  10. Kim M, Kang M, Kim S, Jang S, Min K, Yoo S. UCB therapy in acquired brain injury. 2012–2014. https://clinicaltrials.gov/ct2/show/NCT01885663?term=UCB+Therapy+in+Acquired+Brain+Injury.&rank=1. Accessed 30 Nov 2015.

  11. Kurtzberg J. A randomized study of autologous umbilical cord blood reinfusion in children with cerebral palsy. 2010–2016. https://clinicaltrials.gov/ct2/show/NCT01147653?term=NCT01147653&rank=1. Accessed 30 Nov 2015.

  12. Kurtzberg J, Sun J. Assessment of the safety of allogeneic umbilical cord blood infusions in children with cerebral palsy. 2015–2018. https://clinicaltrials.gov/ct2/show/NCT02599207?term=NCT02599207&rank=1. Accessed 30 Nov 2015.

  13. Lee J, Rajadurai S, Yeo LC. Autologous cord blood cells for brain injury in term newborns. 2011–2015. https://clinicaltrials.gov/ct2/show/NCT01649648?term=NCT01649648&rank=1. Accessed 30 Nov 2015.

  14. Shintaku H. Autologous cord blood cell therapy for neonatal encephalopathy. 2014–2018. https://clinicaltrials.gov/ct2/show/NCT02256618?term=NCT02256618&rank=1. Accessed 30 Nov 2015.

  15. Yin Z. Neuroprotective effect of autologous cord blood combined with therapeutic hypothermia following neonatal encephalopathy. 2015–2018. https://clinicaltrials.gov/ct2/show/NCT02605018?term=NCT02605018&rank=1. Accessed 30 Nov 2015.

  16. Zhou W. Neuroprotective effect of autologous cord blood combined with therapeutic hypothermia following neonatal encephalopathy. 2015–2018. https://clinicaltrials.gov/ct2/show/NCT02551003?term=NCT02551003&rank=1. Accessed 30 Nov 2015.

  17. Chen G, Wang Y, Xu Z, Fang F, Xu R, Hu X, et al. Neural stem cell-like cells derived from autologous bone mesenchymal stem cells for the treatment of patients with cerebral palsy. J Transl Med. 2013;11:21. https://doi.org/10.1186/1479-5876-11-21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Cotten CM, Murtha AP, Goldberg RN, Grotegut CA, Smith PB, Goldstein RF, et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. J Pediatr. 2014;164(5):973–979.e1. https://doi.org/10.1016/j.jpeds.2013.11.036.

    Article  PubMed  Google Scholar 

  19. Kang M, Min K, Jang J, Kim SC, Kang MS, Jang SJ, et al. Involvement of immune responses in the efficacy of cord blood cell therapy for cerebral palsy. Stem Cells Dev. 2015;24(19):2259–68. https://doi.org/10.1089/scd.2015.0074.

    Article  CAS  PubMed  Google Scholar 

  20. Luan Z, Liu W, Qu S, Du K, He S, Wang Z, et al. Effects of neural progenitor cell transplantation in children with severe cerebral palsy. Cell Transplant. 2012;21(Suppl 1):S91–8. https://doi.org/10.3727/096368912X633806.

    Article  PubMed  Google Scholar 

  21. Luan Z, Qu S, Du K, Liu W, Yang Y, Wang Z, et al. Neural stem/progenitor cell transplantation for cortical visual impairment in neonatal brain injured patients. Cell Transplant. 2013;22(Suppl 1):S101–12. https://doi.org/10.3727/096368913X672163.

    Article  PubMed  Google Scholar 

  22. Hassan MA, Gabr H, Fathi S, Ramzy GM, El-Hassany AH, Abd El-Ghaffar NA. Stem cell transplantation in Egyptian patients with cerebral palsy. Egypt J Neuro Psychiat Neurosurg. 2012;49(2):117–22.

    Google Scholar 

  23. Mancias-Guerra C, Marroquin-Escamilla AR, Gonzalez-Llano O, Villarreal-Martinez L, Jaime-Perez JC, Garcia-Rodriguez F, et al. Safety and tolerability of intrathecal delivery of autologous bone marrow nucleated cells in children with cerebral palsy: an open-label phase I trial. Cytotherapy. 2014;16(6):810–20. https://doi.org/10.1016/j.jcyt.2014.01.008.

    Article  CAS  PubMed  Google Scholar 

  24. Min K, Song J, Kang JY, Ko J, Ryu JS, Kang MS, et al. Umbilical cord blood therapy potentiated with erythropoietin for children with cerebral palsy: a double-blind, randomized, placebo-controlled trial. Stem Cells. 2013;31(3):581–91. https://doi.org/10.1002/stem.1304.

    Article  CAS  PubMed  Google Scholar 

  25. Wang X, Cheng H, Hua R, Yang J, Dai G, Zhang Z, et al. Effects of bone marrow mesenchymal stromal cells on gross motor function measure scores of children with cerebral palsy: a preliminary clinical study. Cytotherapy. 2013;15(12):1549–62. https://doi.org/10.1016/j.jcyt.2013.06.001.

    Article  PubMed  Google Scholar 

  26. Pimentel-Coelho PM, Magalhaes ES, Lopes LM, deAzevedo LC, Santiago MF, Mendez-Otero R. Human cord blood transplantation in a neonatal rat model of hypoxic-ischemic brain damage: functional outcome related to neuroprotection in the striatum. Stem Cells Dev. 2010;19(3):351–8. https://doi.org/10.1089/scd.2009.0049.

    Article  PubMed  Google Scholar 

  27. Xia G, Hong X, Chen X, Lan F, Zhang G, Liao L. Intracerebral transplantation of mesenchymal stem cells derived from human umbilical cord blood alleviates hypoxic ischemic brain injury in rat neonates. J Perinat Med. 2010;38(2):215–21. https://doi.org/10.1515/JPM.2010.021.

    Article  PubMed  Google Scholar 

  28. Meier C, Middelanis J, Wasielewski B, Neuhoff S, Roth-Haerer A, Gantert M, et al. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. Pediatr Res. 2006;59(2):244–9. https://doi.org/10.1203/01.pdr.0000197309.08852.f5.

    Article  PubMed  Google Scholar 

  29. MHLW. Ministry of Health, Labour and Welfare. http://www.mhlw.go.jp/english/. Accessed 11 Nov 2015.

  30. PMDA. Pharmaceutical and Medical Devices Agency. http://www.pmda.go.jp/english/index.html. Accessed 11 Nov 2015.

  31. FDA. U.S. Food and Drug Administration. http://www.fda.gov/default.htm. Accessed 11 Nov 2015.

  32. EMA. European Medicines Agency. http://www.ema.europa.eu/ema/. Accessed 11 Nov 2015.

  33. ICH. The international council for harmonisation of technical requirements for pharmaceuticals for human use. http://www.ich.org/home.html. Accessed 11 Nov 2015.

Download references

Author information

Authors and Affiliations

  1. Department of Health Policy, National Center for Child Health and Development, Tokyo, Japan

    Noriko Takahashi Ph.D. & Rintaro Mori M.D., Ph.D.

Authors
  1. Noriko Takahashi Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rintaro Mori M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pediatrics, Osaka City University Graduate School of Medicine, Osaka, Japan

    Haruo Shintaku

  2. Department of Pediatrics, University of Tokyo, Tokyo, Japan

    Akira Oka

  3. Department of Pediatrics, Yodogawa Christian Hospital, Osaka, Japan

    Makoto Nabetani

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Takahashi, N., Mori, R. (2018). Clinical Trials on Cell Therapy for Perinatal Brain Injury: Challenges and Opportunities. In: Shintaku, H., Oka, A., Nabetani, M. (eds) Cell Therapy for Perinatal Brain Injury. Springer, Singapore. https://doi.org/10.1007/978-981-10-1412-3_13

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-1412-3_13

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-1411-6

  • Online ISBN: 978-981-10-1412-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation